ruxolitinib is a medication that belongs to a class of drugs known as JAK inhibitors. It works by inhibiting the activity of certain enzymes called Janus kinases (JAKs), which are involved in signaling pathways that regulate the immune system and the growth and development of blood cells
By inhibiting JAKs, ruxolitinib reduces inflammation and modulates the immune response, which can be beneficial in treating conditions such as myelofibrosis, a type of bone marrow cancer, and polycythemia vera, a rare blood disorder. It can also treat graft-versus-host disease, a complication that can occur after a stem cell or bone marrow transplant
The spectrum of activity of ruxolitinib is primarily limited to treating these specific conditions. It is not effective in treating other types of cancer or autoimmune disorders.
